58880-19-6 | Trichostatin A (TSA)

Chemical type

• Histone deacetylase (HDAC) inhibitor

^[1]

• Histone deacetylase (HDAC) inhibitor, specifically targeting HDAC4

^[2]

Key properties

• Potent epigenetic modulator
• Increases histone acetylation, leading to chromatin relaxation
• Enhances reprogramming efficiency and reduces variability between cell lines

^[1]

• Potent modulator of gene expression through histone acetylation alteration
• Bioactive organic compound with ability to inhibit HDAC4 expression and activity
• Reverses burn-induced protein upregulation (e.g., HDAC4 and myogenin)
• Administered subcutaneously at 0.6 mg/kg/day

^[2]

• Accelerates and improves the efficiency of fibroblast-to-neuroectodermal conversion
• Combined with Dorsomorphin to shorten the protocol from ~21 days to 12 days and boost efficiency to ~24%

^[1]

• Pharmacological agent to mitigate non-depolarizing muscle relaxant (NDMR) resistance in burn-injured skeletal muscle
• Inhibitor of HDAC4-myogenin pathway to counteract denervation-like responses post-burn
• Therapeutic candidate for neuromuscular disorders related to burns or denervation

^[2]

Classification by use

• Epigenetic modulators in reprogramming
• HDAC inhibitors
• Small molecules for transdifferentiation

^[1]

• Chemicals used as epigenetic modulators
• Chemicals used in neuromuscular pharmacology
• Chemicals used in burn injury treatment research

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Full small molecule conversion of human fibroblasts to neuroectodermal cells via a cocktail of Dorsomorphin and Trichostatin A, Regenerative Therapy, Volume 15, December 2020, Pages 44-52
2. [Cite:2] Trichostatin A reverses Silver sulfadiazine resistance in burn-injured rats, Burns, Volume 51, Issue 2, March 2025, 107351